DexCom (NASDAQ: DXCM) officer may sell 2,565 shares on Aug. 27, 2026

Rhea-AI Filing Summary

DexCom, Inc. (DXCM) received a Rule 144 notice from officer Sadie Stern covering a potential sale of common stock. The notice lists 2,565 shares of DexCom common stock to be sold through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate value of $226,669.05 and a proposed sale date of 08/27/2026. The shares trace to restricted stock originally acquired from the issuer, including 1,874 shares acquired on 03/08/2024 and 691 shares acquired on 12/15/2023.

Key Figures

Shares of common stock to be sold: 2,565 shares Aggregate value of shares: $226,669.05 Proposed sale date: 08/27/2026 +2 more

5 metrics

Shares of common stock to be sold 2,565 shares Total DexCom common shares listed in the Form 144 notice

Aggregate value of shares $226,669.05 Aggregate market value for 2,565 DexCom common shares in the notice

Proposed sale date 08/27/2026 Date on which the Form 144 indicates the shares may be sold

Restricted stock acquired 03/08/2024 1,874 shares Restricted DexCom common stock acquired from issuer on 03/08/2024

Restricted stock acquired 12/15/2023 691 shares Restricted DexCom common stock acquired from issuer on 12/15/2023

Key Terms

Rule 144, Restricted Stock, NASDAQ

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock financial

"Common | 03/08/2024 | Restricted Stock | ISSUER"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

NASDAQ market

"| 377360765 | 08/27/2026 | NASDAQ"

The Nasdaq is a stock exchange where many companies' shares are bought and sold, functioning much like a marketplace for investments. It matters to investors because it provides a platform to buy and sell ownership stakes in companies, helping them track the value of those companies and make informed decisions. As one of the largest and most technology-focused markets, it also reflects trends and developments in the business world.

FAQ

What does Sadie Stern’s Form 144 filing mean for DexCom (DXCM)?

The filing gives notice under Rule 144 that officer Sadie Stern may sell 2,565 shares of DexCom common stock. It is a disclosure of a potential future sale and does not itself execute any transaction.

How many DexCom (DXCM) shares are covered by this Form 144?

The notice covers 2,565 shares of DexCom common stock. These shares come from restricted stock awards of 1,874 shares acquired on 03/08/2024 and 691 shares acquired on 12/15/2023 from the issuer.

What is the estimated value of the DexCom (DXCM) shares in this Form 144?

The Form 144 lists an aggregate value of $226,669.05 for the 2,565 shares of DexCom common stock that may be sold under this notice.

When could the Form 144 shares of DexCom (DXCM) be sold?

The notice states a proposed sale date of 08/27/2026 for the 2,565 shares of DexCom common stock. Rule 144 notices disclose an intention to sell, subject to applicable conditions.

Through which broker and market might the DexCom (DXCM) shares be sold?

The Form 144 identifies Morgan Stanley Smith Barney LLC as the broker and indicates that the 2,565 shares of DexCom common stock may be sold on NASDAQ.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/27/2026 - 04:11 PM Accepted by SEC EDGAR 08/27/2026 - 04:10 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001797971
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	DEXCOM, INC.
SEC File Number	000-51222
Address of Issuer	6340 Sequence Drive San Diego CALIFORNIA 92121
Phone	(858) 200-0200
Name of Person for Whose Account the Securities are To Be Sold	SADIE STERN
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	2565	226669.05	377360765	08/27/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/08/2024	Restricted Stock	ISSUER			1874	03/08/2024	Not Applicable
Common	12/15/2023	Restricted Stock	ISSUER			691	12/15/2023	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	08/27/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/28/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Sadie Stern
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)